Targeting LARG with Y16 in neuroblastoma has been shown to promote differentiation, induce MYCN degradation, and reduce tumorigenicity, suggesting a translatable therapeutic approach for targeting LARG (35). This evidence concerns the gene ARHGEF12 and neuroblastoma.